Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.37 |
| ▸ | DRD3 | P35462 | 7/20 | 0.37 |
| ▸ | DRD4 | P21917 | 5/20 | 0.37 |
| ▸ | DRD1 | P21728 | 3/20 | 0.37 |
| ▸ | DRD5 | P21918 | 3/20 | 0.37 |
| ▸ | PDE2A | O00408 | 4/20 | 0.35 |
| ▸ | PDE1A | P54750 | 3/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.35 |
| ▸ | HTR1D | P28221 | 2/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070525 | 0.80 | PDE1A (0.39) | PDE2APDE1APDE1BPDE1C | |
| SCHEMBL8025948 | 0.65 | DRD2 (0.42) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL13604212 | 0.63 | DRD2 (0.46) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL22140929 | 0.62 | KDM4E (0.42) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL3104662 | 0.62 | DRD2 (0.39) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL22140918 | 0.61 | MEN1 (0.41) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL22140916 | 0.61 | KDM4E (0.36) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL25323447 | 0.61 | FABP1 (0.39) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL23043440 | 0.61 | TSHR (0.46) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL30707207 | 0.61 | CCR4 (0.40) | DRD2DRD3DRD4DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| EP-1732541-A4 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| EP-1732541-A2 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005099688-A2 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | DRD2 179/4885DRD3 206/4885DRD4 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.